RDY.US
RDY.US

Last Day

Drug Manufacturers – Specialty & Generic

Latest Valuation

  • Trailing PE:
  • Forward PE:
  • Price Sales TTM:
  • Price Book MRQ:
  • Enterprise Value:
  • Enterprise Value Revenue:
  • Enterprise Value Ebitda:
  • Beta:

Key Highlights

  • Shares Outstanding:
  • Market Capitalization:
  • Market Capitalization Mln:
  • EBITDA:
  • PE Ratio:
  • PEG Ratio:
  • Wall Street Target Price:
  • Book Value:
  • Dividend Share:
  • Dividend Yield:
  • Earnings Share:
  • EPS Estimate Current Year:
  • EPS Estimate Next Year:
  • EPS Estimate Next Quarter:
  • EPS Estimate Current Quarter:
  • Most Recent Quarter:
  • Profit Margin:
  • Operating Margin TTM:
  • Return On Assets TTM:
  • Return On Equity TTM:
  • Revenue TTM:
  • Revenue Per Share TTM:
  • Quarterly Revenue Growth YOY:
  • Gross Profit TTM:
  • Diluted Eps TTM:
  • Quarterly Earnings Growth YOY:

Basic Information

  • Type:
  • Name:
  • Exchange:
  • Currency Code:
  • Currency Name:
  • Currency Symbol:
  • Country Name:
  • Fiscal Year End:
  • IPO Date:
  • International Domestic:
  • Sector:
  • Industry:
  • Address:
  • Country:
  • Listings:
  • Web URL:
  • Full Time Employees:
  • Updated At:
  • Gic Sector:
  • Gic Group:
  • Gic Industry:
  • Gic SubIndustry:

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Address: 8-2-337, Road No. 3, Hyderabad, India, 500034

2024-6-30